• Celltrion Pharm disclosed plans on Nov. 13, 2026, to deliver 553 treasury shares to settle a stock option exercise.
• A non-registered executive exercised options covering 946 shares at KRW 16,650 per share.
• The shares will be transferred between Nov. 19, 2026, and March 27, 2027, with a stated disposal value of KRW 9.21 million.
• Settlement covers the option gains in treasury shares rather than requiring payment of the exercise price.
• The exercise exhausts the remaining options from the March 28, 2017, grant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celltrion Pharm Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261113000892), on November 13, 2026, and is solely responsible for the information contained therein.